CSIMarket Company Name, Ticker, Industry, else..
 
Xtant Medical Holdings Inc   (NYSEAMER: XTNT)
Other Ticker:  
 
 
Price: $0.5400 $0.06 12.523%
Day's High: $0.54 Week Perf: 12.73 %
Day's Low: $ 0.45 30 Day Perf: -8.63 %
Volume (M): 92 52 Wk High: $ 1.24
Volume (M$): $ 50 52 Wk Avg: $0.63
Open: $0.46 52 Wk Low: $0.33



 Market Capitalization (Millions $) 73
 Shares Outstanding (Millions) 135
 Employees 170
 Revenues (TTM) (Millions $) 113
 Net Income (TTM) (Millions $) -18
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 4

Xtant Medical Holdings Inc
Xtant Medical Holdings Inc is a medical devices company that specializes in the design, development, and commercialization of regenerative medicine products and medical implant products. The company offers a wide range of products for orthopedic and neurological surgeries, including spinal implants, biologics, and orthobiologics. Xtant Medical Holdings Inc is focused on improving patient outcomes and quality of life through innovative solutions and technologies. The company operates globally and collaborates with healthcare professionals, hospitals, and medical institutions to provide effective and reliable solutions for various medical conditions.


   Company Address: 664 Cruiser Lane Belgrade 59714 MT
   Company Phone Number: 388-0480   Stock Exchange / Ticker: NYSEAMER XTNT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
VCEL   -2.82%    
IART   -2.72%    
JNJ   -0.58%    
MDT   -2.26%    
OFIX   -0.89%    
SYK   -0.44%    
• View Complete Report
   



Xtant Medical Holdings Inc

Xtant Medical Holdings Inc. Delivers Impressive Results in Q1 2024

The stock market is always filled with interesting developments and trends that can often catch investors by surprise. One recent example of this is Xtant Medical Holdings Inc, a biotechnology and pharmaceutical company that has defied expectations and shown impressive growth in a challenging industry.
In the financial time-frame closing on March 31, 2024, Xtant Medical Holdings Inc reported an increase in deficit per share from $-0.02 to $-0.03 compared to the previous year. Furthermore, the company saw a growth in deficit from $-0.02 per share from the prior financial reporting period. Despite these negative figures, Xtant Medical Holdings Inc managed to impress investors with its revenue growth.
Product Service News

Xtant Medical Leaps Forward: Introduces SimpliGraft and SimpliMax for Advanced Wound Care

Published Tue, Apr 30 2024 9:00 AM UTC

With the advent of continuous innovation, the face of medical treatments is ever-changing. One company making strides in the field is Xtant Medical Holdings, Inc., a prominent global name in the medical technology industry known for its advanced surgical solutions for spinal disorders. Continuing with their role as trailblazers, Xtant recently announced the full commercial l...
Financing Agreement

Xtant Medical Fortifies Financial Foundation with $17 Million Revolving Credit Facility Expansion

Published Thu, Mar 7 2024 9:05 PM UTC

Xtant Medical Holdings, Inc. Expands Financing Options to Fuel Growth
BELGRADE, Mont., March 07, 2024 - Xtant Medical Holdings, Inc. (NYSE American: XTNT) has made significant moves to strengthen its financial position and support its growth strategy in the spinal surgery solutions market. The company recently announced amendments to its revolving credit agreement and te...
Xtant Medical Holdings Inc

Compelling period by the Xtant Medical Holdings Inc all along the most recent fiscal period

Xtant Medical Holdings Inc Turns Profitable, Signaling Strong Growth Potential
BELGRADE, Mont., Oct. 12, 2023 - Xtant Medical Holdings Inc (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal disorders, has announced impressive financial results for the most recent fiscal period. The company's turnaround to a surplus has caught the attention of investors, with income per share standing at $0.07 compared to a loss of $0.03 per share a year ago. Furthermore, Xtant Medical Holdings Inc achieved a positive income per share of $0.02 in comparison to a loss of $0.02 per share in the preceding reporting period.
One of the key factors contributing to their success is the substantial revenue growth of 68.262%, reaching $24.33 million from $14.46 million in the same reporting period last year. Sequentially, the company also witnessed a notable improvement of 25.053% from $19.46 million. The surge in revenue reflects Xtant Medical Holdings Inc's strong market presence and the increasing demand for its products.
Xtant Medical Holdings Inc

Xtant Medical Holdings Records a Substantial 32.434% Increase in Revenue in Q2 2023, Outperforms Biotechnology & Pharmaceuticals Industry



In the financial second quarter of 2023, Xtant Medical Holdings Inc, a leading biotechnology and pharmaceuticals company, reported a loss of $-0.02 per share. However, the company's revenue surged by an impressive 32.434% to $20.23 million compared to the corresponding reporting season a year ago. This positive financial outcome sets Xtant Medical Holdings Inc apart from its industry peers, as most other companies in the biotechnology and pharmaceuticals sector experienced business contraction during the same period.
Revenue Growth and Business Performance:
Xtant Medical Holdings Inc faced a challenging financial environment but managed to exhibit resilience amidst the industry's contraction. The company recorded revenue of $17.94 million and $-0.02 per share in the previous reporting season. Despite incurring a net loss of $-2.190 million for the financial interval ending June 30, 2023, this loss was still smaller than the $-1.710 million loss reported a year ago.






Xtant Medical Holdings Inc's Segments
Orthobiologics    60.71 % of total Revenue
Spinal Implant    41.59 % of total Revenue
UNITED STATES    92.8 % of total Revenue
Rest of World    9.5 % of total Revenue

  Xtant Medical Holdings Inc Outlook

On April 1 2024 the Xtant Medical Holdings Inc provided following guidance

Xtant Medical Holdings Inc. has reported a record-breaking full year revenue of $91.3 million for 2023. The company is now setting its sights even higher for the upcoming year, with a revenue guidance range of $112 million to $11...





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com